ACAD Gets approval of Trofinetide for Rett Syndrome

 Congrats to $ACAD, its investors, & Rett Syndrome patients on approval of DAYBUE (Trofinetide) for the treatment of Rett Syndrome • Rare genetic disease

• 1st approved drug

• Supported by Phase 3 Lavender trial data.

• No Black Box warning on label

• Nice stock runup to approval ~33%

• BPIQ Big Mover event

• ACAD gets FDA rare pediatric disease voucher

• Value ~$100M

Competitors from BPIQ Company Screener:

$TSHA

$AVXL

$JAZZ

Read more about upcoming PDUFAs

https://www.bpiq.com/post/acad-pdufa-coming-up

FIrst posted 3/11/23

Not legal, tax or investment advice.

#ACAD #trofinetide